Dr. Robert Huizinga reports

KANE BIOTECH ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS

Kane Biotech Inc. has released its third quarter 2025 financial results.

Third quarter 2025 financial highlights (comparatives exclude discontinued STEM Animal Health operations):

• Total revenue for the three months ended Sept. 30, 2025, was $8,499 compared with $1,282,698 in the three months ended Sept. 30, 2024. The vast majority of revenue recorded in the comparative quarter was related to an animal health manufacturing agreement which terminated in Q1 2025 as well as the recognition of revyve product revenue related to a subsequently terminated United States distribution agreement.
• Gross profit (loss) for the third quarter of 2025 was $(5,128), compared with a gross profit of $558,754 for the third quarter of 2024.
• Total operating expenses for the three months ended Sept. 30, 2025, were $538,306 compared with $1,170,064 for the three months ended Sept. 30, 2024. The reduction in operating expenses is due primarily to a reduction in staff, lower short and long-term compensation expenses, and lower business development costs in the current period.
• Net loss for the third quarter of 2025 was $(607,345) compared with a net loss of $(678,636) for the quarter ended Sept. 30, 2024.
• Cash as of Sept. 30, 2025, was $939,062.

Kane Biotech's Sept. 30, 2025, financial statements and the management discussion and analysis with regards thereto are now available on SEDAR+ and the company's website.

Corporate update

Efforts are well under way in all three pillars of Kane's three-pillar strategy to significantly impact wound care in the United States:

1. Conduct a United States-based case series demonstrating the clinical use of revyve;
2. Report data at leading U.S. wound and burn care meetings;
3. Rebuild the U.S. distributor and sales agent network.

In September, Kane announced that it had enrolled 28 participants in its revyve antimicrobial wound gel and Spray U.S. case series studies, exceeding its 25-participant target. Enrolment continues in the case series in order to create a larger patient database.

Kane presented revyve clinical data at the Symposium on Advanced Wound Care (SAWC) fall conference held in September, 2025, where interim chief executive officer Dr. Robert Huizinga met with potential U.S. distributors.

New clinical data demonstrating the performance of Kane's revyve antimicrobial wound gel in diabetic foot ulcer healing was presented at The Diabetic Foot Conference (DFCon 2025) held in October, 2025. The clinical data presented outperformed the standard of care including an average 97-per-cent area wound reduction in four weeks, and 100-per-cent diabetic wound close in less than 12 weeks in the cases presented.

In addition, new preclinical data demonstrating the performance of revyve in burn wound infection control was presented at the Southern Region Burn Conference which was held in October/November, 2025. It was revealed that the use of the revyve resulted in a six-log reduction in microbial load within 30 minutes and sustained antibiofilm activity for a minimum of seven days.

Kane also plans to attend and present at numerous scientific meetings throughout 2025 and 2026, where further results of its case series studies will be presented.

The company completed a U.S. Food and Drug Administration (FDA) 510(k) clearance submission for its revyve antimicrobial wound cleanser.

The company continues to advance its discussions with U.S. distributors and sales agents with the view of building a network of non-exclusive distributors and sales agents to establish and grow revyve sales in the U.S.

"Kane Biotech is making material progress with our U.S. case series on the revyve wound care gel that has exceeded enrollment targets and is producing compelling clinical data that has been presented at industry conferences," said Dr. Robert Huizinga, interim CEO. "Doing so underpins our efforts to rebuild the U.S. distributor network and launch revyve in Canada which reflects our commitment to delivering innovative, high-quality solutions that improve patient outcomes."

About Kane Biotech Inc.

Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve antimicrobial wound gel and revyve antimicrobial wound gel spray are U.S. FDA 510(k) cleared. revyve antimicrobial wound gel is Health Canada approved.

We seek Safe Harbor.